Receptor, TNFR2, Identified as Target for Immunotherapy – Immuno-Oncology News
Immuno-Oncology News |
Receptor, TNFR2, Identified as Target for Immunotherapy
Immuno-Oncology News Antibody immunotherapy is showing great promise for combatting cancer. Several immune checkpoint inhibitors — including Keytruda (pembrolizumab), Opdivo (nivolumab), and Yervoy (ipilimumab) — dampen the tumor's immunosuppressive signals and … |
